Exegenesis Bio to Present Data on Next Generation BBB-penetrating AAV Capsids & Intravitreal nAMD Gene Therapy at the American Society of Gene and Cell Therapy Meeting

Exegenesis Bio to Present Data on Next Generation BBB-penetrating AAV Capsids & Intravitreal nAMD Gene Therapy at the American Society of Gene and Cell Therapy Meeting PHILADELPHIA, PA, May 13, 2025 – Exegenesis Bio, a global gene therapy company developing innovative genetic medicines for eye, CNS and liver -directed diseases is pleased to announce that two oral presentations and three posters will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), May 13-17, 2025 in New Orleans, LA. Oral Presentations Title: Rationally Designed Receptor-targeting AAV Variants Achieved Efficient CNS Transduction in both Mice and NHPs Session: AAV Gene Transfer (A): Crossing the Blood-Brain Barrier Time: 1:45 – 2:00 pm (CT), May 14, 2025 Location: New Orleans Theater C Abstract #: 89 Presenter: Zhenhua Wu, Ph.D., CEO Title: EXG202: A Next Generation AAV-based Gene Therapy for Neovascular AMD Delivered by Intravitreal Injection with Superior Retinal Transduction in NHPs and Remarkable Inhibitory Effect on Retinal Detachment in a Severe Neovascular Mouse Model Session: AAV Preclinical and Proof-of-Concept Studies for Neurological Diseases Time: 5:15 – 5:30 pm (CT), May 16, 2025 Location: New Orleans Theater A Abstract #: 309 Presenter: Zhenhua Wu, Ph.D., CEO Poster Presentations Title: Next-Generation AAV -Based Gene Therapy for Spinal Muscular Atrophy: Safety and Efficacy of EXG001-307 in Clinical Trials Time: 5:30– 7:00 pm (CT), May 14, 2025 Location: Poster Hall Hall I2 Abstract #: 1045 Title: Nonclinical Evaluation of AAV Gene Therapy EXG001-307 for Spinal Muscular Atrophy Time: 5:30– 7:00 pm (CT), May 14, 2025 Location: Poster Hall Hall I2 Abstract #: 1046 Title: A GLP-compliant Toxicology Study of Intravenously Administrated EXG110 for Treating Fabry Disease Time: 5:30– 7:00 pm (CT), May 15, 2025 Location: Poster Hall I2 Abstract #: 1506 For further information please contact: [email protected]

The release as fetched from its publisher. exegenesisbio.com ↗